Inventor · disambiguated record
Kenneth S. Graham
Also filed as: GRAHAM KENNETH · GRAHAM KENNETH S
27 granted patents·10 pending applications·943 citations·filing 1997–2025
97Inventor score
Top patents by PatentIndex Score
37 records- 0199US11084865B2VEGF antagonist formulations suitable for intravitreal administrationREGENERON PHARMA·Filed 2020·Granted Aug 10, 2021·14 cites·64 claims
- 0299US10464992B2VEGF antagonist formulations suitable for intravitreal administrationREGENERON PHARMA·Filed 2018·Granted Nov 5, 2019·60 cites·18 claims
- 0399US10400025B2VEGF antagonist formulations suitable for intravitreal administrationREGENERON PHARMA·Filed 2018·Granted Sep 3, 2019·54 cites·15 claims
- 0499US9914763B2VEGF antagonist formulations suitable for intravitreal administrationREGENERON PHARMA·Filed 2016·Granted Mar 13, 2018·56 cites·12 claims
- 0599US9580489B2VEGF antagonist formulations suitable for intravitreal administrationREGENERON PHARMA·Filed 2016·Granted Feb 28, 2017·67 cites·29 claims
- 0699US9340594B2VEGF antagonist formulations for intravitreal administrationREGENERON PHARMA·Filed 2014·Granted May 17, 2016·73 cites·12 claims
- 0799US8802107B2VEGF antagonist formulations for intravitreal administrationREGENERON PHARMA·Filed 2013·Granted Aug 12, 2014·65 cites·18 claims
- 0899US7807164B2Lyophilized VEGF antagonist formulations for intravitreal administrationREGENERON PHARMA·Filed 2009·Granted Oct 5, 2010·83 cites·9 claims
- 0998US11066458B2VEGF antagonist formulations suitable for intravitreal administrationREGENERON PHARMA·Filed 2019·Granted Jul 20, 2021·12 cites·66 claims
- 1098US8481046B2VEGF antagonist formulations for intravitreal administrationFURFINE ERIC·Filed 2011·Granted Jul 9, 2013·72 cites·9 claims
- 1198US8092803B2VEGF antagonist formulations for intravitreal administrationFURFINE ERIC·Filed 2010·Granted Jan 10, 2012·136 cites·19 claims
- 1297US11732024B2VEGF antagonist formulations suitable for intravitreal administrationREGENERON PHARMA·Filed 2021·Granted Aug 22, 2023·2 cites·60 claims
- 1397US9173880B2Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodiesDIX DANIEL B·Filed 2011·Granted Nov 3, 2015·96 cites·17 claims
- 1497US7608261B2VEGF antagonist formulations suitable for intravitreal administrationREGENERON PHARMACUTICALS INC·Filed 2007·Granted Oct 27, 2009·131 cites·17 claims
- 1595US12331099B2VEGF antagonist formulations suitable for intravitreal administrationREGENERON PHARMA·Filed 2024·Granted Jun 17, 2025·0 cites·30 claims
- 1693US10072086B2Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodiesREGENERON PHARMA·Filed 2015·Granted Sep 11, 2018·12 cites·26 claims
- 1791US11103552B2High concentration VEGF receptor fusion protein containing formulationsREGENERON PHARMA·Filed 2019·Granted Aug 31, 2021·8 cites·36 claims
- 1890US2023374108A1Vegf antagonist formulations suitable for intravitreal administrationREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 1987US2025197515A1Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodiesREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 2087US2025257118A1Vegf antagonist formulations suitable for intravitreal administrationREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 2185US11098127B2Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodiesREGENERON PHARMA·Filed 2018·Granted Aug 24, 2021·1 cites·27 claims
- 2284US12440622B2Devices and methods for overfilling drug containersREGENERON PHARMA·Filed 2024·Granted Oct 14, 2025·0 cites·20 claims
- 2382US2025121030A1High Concentration VEGF Receptor Fusion Protein Containing FormulationsREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 2481US11918785B2Devices and methods for overfilling drug containersREGENERON PHARMA·Filed 2023·Granted Mar 5, 2024·0 cites·17 claims
- 2580US2024058418A1High Concentration VEGF Receptor Fusion Protein Containing FormulationsREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2677US12077593B2Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodiesREGENERON PHARMA·Filed 2021·Granted Sep 3, 2024·0 cites·27 claims
- 2774US12168036B2Methods for treating angiogenic eye disorders with high doses of VEGF receptor fusion proteinsREGENERON PHARMA·Filed 2021·Granted Dec 17, 2024·0 cites·38 claims
- 2871US12436152B2Methods for predicting and modulating glycation of a proteinREGENERON PHARMA·Filed 2022·Granted Oct 7, 2025·0 cites·10 claims
- 2966US11071780B2Methods and formulations for treating vascular eye diseases using aflibercept and nesvacumabREGENERON PHARMA·Filed 2018·Granted Jul 27, 2021·0 cites·9 claims
- 3066US2025041411A1Stabilized Formulations Containing Anti-BCMA x Anti-CD3 Bispecific AntibodiesREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 3166US2024245779A1Methods of modeling liquid protein composition stabilityREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 3258US11577025B2Devices and methods for overfilling drug containersREGENERON PHARMA·Filed 2017·Granted Feb 14, 2023·0 cites·22 claims
- 3358US2022332849A1Stabilized Formulations Containing Anti-MUC16 x Anti-CD3 Bispecific AntibodiesREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 3456US12472253B2Activin a antibody formulations and methods of use thereofREGENERON PHARMA·Filed 2021·Granted Nov 18, 2025·0 cites·23 claims
- 3549US2017080086A1Methods and formulations for treating vascular eye diseasesREGENERON PHARMA·Filed 2016·Application pending·0 cites
- 3646US2016144025A1Methods and formulations for treating vascular eye diseasesREGENERON PHARMA·Filed 2015·Application pending·0 cites
- 3737US5986071AMethod for C-terminal degradation of peptides and proteinsHOPE CITY·Filed 1997·Granted Nov 16, 1999·1 cites·23 claims
Join the waitlist — get patent alerts
Get an alert when Kenneth S. Graham files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →